
Tauriga Sciences adds venture capitalist
pharmafile | January 21, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Hingge Hsu, tauriga sciences
US life sciences firm Tauriga Sciences has appointed Dr Hingge Hsu to its board of directors.
Hsu was recently a partner at Fidelity Biosciences and on the healthcare investment team for Fidelity Growth Partners Asia. Prior to that he was a managing director at Lehman Brothers in its private equity group.
Also a partner at Schroder Ventures Life Sciences from 1998 to 2001, he directed their US investment activities in the life sciences and therapeutics sectors. Hingge has also served on a number of boards including most recently that of NextWave Pharmaceuticals.
Tauriga’s chairman and chief executive Dr Stella Sung says: “I am pleased to have Dr Hingge Hsu join our board of directors at this pivotal time. His transactional and business development expertise and his understanding of Asian markets will be invaluable to Tauriga.”
Hsu adds: “I look forward to using my strategic and transactional experience to help Tauriga grow its business opportunities and geographical reach.”






